, ,

Mylan representatives intend to fight the $18 million judgment, which found patent infringement for an ashma inhaler product.  The Mylan CEO told Pittsburgh Business Times that while the inhaler was “not a significant product for Mylan,” it would file post-judgment motions to reverse the verdict. 

She said the company would appeal the verdict and damage award “if necessary.” Those don’t really sound like fighting words to me — sounds like Mylan is going to file a motion for judgment notwithstanding the verdict and then, if it loses, will say “Eh, it wasn’t a very important product anyway.”  But time will tell. I am sure that case was keeping a lot of attorneys busy around here.

[Pittsburgh Business Times]